查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837270

通用感染疾病治療市場（按疫苗、治療、診斷和支持性護理分類）－全球預測（2025-2032年）

Zoonotic Disease Treatment Market by Vaccines, Therapeutics, Diagnostics, Supportive Care - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，通用感染疾病治療市場規模將達到 621.9 億美元，複合年成長率為 5.61%。

關鍵市場統計數據
基準年2024年 401.6億美元
預計年份：2025年 424.4億美元
預測年份 2032 621.9億美元
複合年成長率 (%) 5.61%

全面概述通用感染疾病威脅情勢以及保護人群所需的綜合臨床和公共衛生應對措施

通用感染疾病仍然是人類和動物健康面臨的持續且不斷演變的威脅，需要公共衛生、臨床醫學和商業相關人員之間協調應對。全球旅行、土地利用變化以及人畜接觸介面的轉變，加劇了病原體溢出事件的發生，也使得加強預防、診斷和治療能力變得特別迫切。因此，應對機構必須兼顧近期臨床需求與對平台技術和衛生系統韌性的長期投資。

在此背景下，決策者必須採用一個整合框架，將疫苗研發、治療方法創新、診斷部署和支援性醫療服務連結起來。有效的治療方法依賴快速且準確的診斷，疫苗策略以基因組監測為依據，而支持性醫療服務能力則是嚴重通用感染疾病臨床療效的基礎。此外，公私合作對於將科學進步轉化為可推廣至不同醫療機構的可擴展干預措施至關重要。

因此，相關人員應優先考慮可互通的監測系統、適應性強的生產能力和實證臨床路徑。這些優先事項既反映了病原體生物學的技術現實，也反映了限制實際影響的後勤限制。如本執行摘要所述，科學創新與務實營運設計的融合將決定衛生系統如何應對通用感染疾病帶來的下一個挑戰。

近年來，平台創新、不斷變化的監管環境以及「同一健康」理念的成熟，顯著改變了通用感染疾病治療格局。基於套件的疫苗平台，特別是那些能夠快速設計抗原和實現規模化生產的平台，加快了從序列到候選藥物的研發進程；同時，單株抗體和小分子抗病毒藥物的同步進展也豐富了治療手段。此外，監管路徑也在進行調整，以適應基於平台的核准和加速審查機制，顯著降低了快速部署的門檻。

PCR和次世代定序等分子生物學技術與即時檢測方法相輔相成，能夠更早檢測和鑑定病原體。這種診斷流程有助於制定更有針對性的治療方案，並減少不必要的抗生素使用。同時，數位健康工具和數據整合平台能夠實現近乎即時的監測和病患管理，將本地資訊與醫院的回應能力連結起來。

同時，戰略重心正轉向綜合性緊急準備資金籌措和多部門合作。公共和私人資助者擴大為生態系統層面的投資提供資金，例如突波生產能力和實現供應鏈多元化，以降低疫情爆發期間供不應求的風險。因此，那些兼具科學敏捷性和運作嚴謹性的機構，最能將這種轉變轉化為更佳的臨床療效和更持久的韌性。

從策略角度評估不斷變化的關稅政策將如何改變供應鏈、採購慣例以及診斷試劑、治療藥物和疫苗的永續取得途徑。

貿易和關稅政策的調整將對關鍵醫療對策的取得及其供應鏈產生重大影響。影響原料、活性藥物成分、診斷試劑和成品生技藥品的關稅變化會產生連鎖反應，進而改變整個醫療生態系統的採購籌資策略、庫存管理和採購決策。當關稅增加成本或造成不確定性時，企業通常會透過延長供應鏈、加快生產在地化以及優先儲備策略緩衝庫存來應對。

除了影響採購之外，關稅還將再形成製造商和合約服務提供者的商業性考量。關稅會影響諸如生產設施選址、是否投資冗餘設備以及如何為不同市場制定產品價格等決策。重要的是，這些政策變化會與現有的監管和物流限制相互作用，從而在成本、速度和供應安全之間形成複雜的權衡。對於應對疫情的衛生系統而言，當務之急是確保診斷、治療和疫苗的持續供應。

因此，相關人員應將關稅環境視為一項策略風險，需要進行情境規劃並與貿易當局積極溝通。企業可以透過以下方式降低風險：實現供應商基礎多元化，拓展不同司法管轄區；投資模組化和靈活的生產技術；制定考慮進口關稅和潛在監管摩擦的合約策略。最終，基於穩健的政策分析做出採購和生產決策，有助於臨床和商業領導者即使在地緣政治或貿易政策動盪時期也能維持治療方案的正常運作。

深入的細分主導分析揭示了疫苗、治療藥物、診斷方法和支持性護理之間的差異，從而確定臨床優先事項和商業策略。

有效的細分市場分析能夠揭示最有可能影響臨床結果和商業性可行性的投資方向和營運重點。在疫苗領域，預防性疫苗和治療性疫苗之間的差異決定了研發重點和生產佈局。預防性疫苗包括減毒疫苗、結合疫苗、mRNA疫苗和重組疫苗，每種疫苗都有其自身的低溫運輸、佐劑和監管方面的考量。治療性疫苗同樣包括減毒疫苗、結合疫苗、mRNA疫苗和重組疫苗，但它們的研發採用不同的療效終點和臨床試驗設計，這會影響其市場進入時間和醫師接受度曲線。

治療藥物細分同樣揭示了臨床和供應方面的動態變化。抗生素、抗真菌藥物、抗寄生蟲藥和抗病毒藥是核心治療類別。抗生素又細分為BETA-內醯胺類、大環內酯類和四環黴素，每種抗生素都有其獨特的傳統生產基礎設施和管理要求。抗黴菌藥物主要集中在Azole和Polyenes，每種藥物都有不同的藥物動力學和毒性特徵。同時，抗寄生蟲策略分為驅蟲藥和抗寄生蟲藥，需要標靶給藥方式。抗病毒藥物物組合，包括單株抗體、核苷類似物和蛋白酶抑制劑，需要先進的生技藥品或合成化學能力，並與診斷平台緊密結合才能合理使用。

診斷細分凸顯了建構涵蓋影像、分子診斷、照護現場工具和血清學的生態系統方法的重要性。放射影像和超音波等影像學方法支援臨床分診和併發症評估，而分子診斷則利用次世代定序和PCR技術進行病原體鑑定和基因組監測。照護現場橫向流動化驗可在分散式醫療環境中實現快速篩檢，而包括ELISA和快速檢測在內的血清學檢測則有助於深入了解流行病學背景和免疫反應。支持性治療，包括輸液、營養和疼痛管理，為必要的臨床干預措施提供了框架，這些干預措施可進一步細分為鎮痛藥和非類固醇消炎劑。

綜合來看，這些細分視角展現了臨床需求與製造可行性和商業性潛力之間的交集，指南跨平台和產品類別的優先投資。

從區域策略觀點出發，協調製造能力、監管多樣性和物流現實，以實現公平獲得治療和診斷。

區域動態影響醫療服務的現狀以及研發和分銷的策略方針。美洲擁有高度集中的先進生物製造生態系統、強大的臨床試驗能力以及複雜的支付方格局。這些因素有利於高通量平台技術和先進診斷整合的發展，同時也為服務不足的人口帶來了成本和可近性的挑戰。相較之下，歐洲、中東和非洲的法規環境和醫療基礎設施成熟度各不相同，集中化的監管協調工作與區域特有的採購慣例和低溫運輸物流能力存在差異並存。

亞太地區的特點是製造業規模快速擴大、學名藥生產能力強勁以及研發密集型營業單位不斷擴展。該地區的多樣性體現在既有高產能的都市區，也有依賴即時醫療和分散式供應模式的偏遠地區。氣候變遷和土地利用模式的改變將影響所有地區的通用感染疾病風險狀況，因此需要製定針對特定區域的監測和社區參與策略。

因此，策略必須因地制宜。生產和供應計畫必須反映當地的監管要求和物流限制，臨床實施工作必須與支付方的動態和醫療系統的工作流程相符。夥伴關係，例如技術轉移協議、與監管機構的合作以及共用監測平台，可以促進公平取得醫療資源，並在疫情爆發時縮短回應時間。

疫苗、治療和診斷試劑供應商之間競爭激烈的市場動態和夥伴關係主導策略決定了市場定位和營運優勢。

通用感染疾病治療領域的競爭格局由多家實力雄厚的製藥公司、專業生物技術公司、診斷試劑生產商以及靈活的合約研發受託製造廠商共同主導。產業領導者透過投資平台技術來縮短研發前置作業時間並實現快速規模化生產，從而實現差異化競爭。同時，專注於分子診斷和生技藥品的專業公司正透過定向創新和利基臨床合作，在市場中扮演關鍵角色。

策略聯盟和夥伴關係正日益成為推動產品研發和進入市場的關鍵。平台所有者與區域製造商之間的共同開發契約有助於彌補產能缺口，而與學術機構和公共衛生機構的合作則能提供病原體生物學和臨床試驗網路方面的深厚專業知識。智慧財產權策略與公共衛生緊急情況下廣泛獲取的需求之間需要取得平衡，這促使人們尋求創新的許可和技術轉移安排。

能夠展現可靠供應連續性、透明品質系統和清晰監管路徑的公司將獲得優先採購權，並增強臨床醫生的信任。此外，那些能夠根據臨床實踐調整產品設計（例如採用耐熱配方、簡化給藥方式和整合診斷功能）的參與企業，將更快地被市場接受。在這種環境下，那些將科學領先地位與規模化生產和切實可行的商業化策略相結合的公司，將保持最具永續性的競爭優勢。

為產業領導者提供切實可行的優先行動方案，以增強生產彈性，協調診斷和治療，並在疫情爆發情況下維持公平的醫療資源取得。

行業領導者應優先採取一系列切實可行的措施，將創新與營運韌性和可及性相結合。首先，投資於模組化和平台化製造方法，以實現疫苗和生物製藥候選產品的快速改造，從而能夠靈活應對新出現的病原體。將這種能力與多元化的關鍵原料供應商網路結合，可以降低單點故障的風險。

第二，我們將透過發展協同解決方案，將診斷整合到治療策略中，把快速分子檢測和即時檢測與合適的治療路徑連結起來。這將減少不必要的抗生素使用，並透過標靶治療改善臨床療效。第三，我們將加強抗菌藥物和抗病毒藥物管理框架，並與臨床醫生和公共衛生部門合作，使處方與監測數據和抗藥性趨勢保持一致。第四，我們將積極與監管機構溝通，利用我們平台技術的核准批准，並簡化試驗設計，以產生可靠的證據，同時加快藥物的可及性。

第五，納入數位監控和數據共用協議，以促進公共和私營部門相關人員之間近乎即時的態勢感知。最後，制定公平的准入策略，包括彈性價格設定、技術轉移以及在資源匱乏地區開展能力建設，以確保干預措施惠及最需要的患者。協調一致地實施這些措施，將提高高風險治療領域商業模式的準備和永續性。

我們採用透明的混合方法研究途徑，結合專家訪談、系統性回顧和三角驗證，為決策者提供可靠且可操作的見解。

本研究採用混合方法，整合了一手和二手研究，旨在獲得可操作且檢驗的見解。一手研究包括對疫苗、治療和診斷機構的臨床負責人、法規事務專業人員、供應鏈經理和高階主管進行結構化訪談，以了解營運限制和策略重點的背景。二手研究包括對同行評審文獻、監管指導文件、技術白皮書和公共衛生報告進行系統性回顧，以從現有的​​科學和政策趨勢中獲取見解。

為消除分歧並檢驗主題結論，我們採用了資料三角測量法。定量數據，例如生產前置作業時間、臨床試驗設計參數和監管申報流程，與專家諮詢獲得的定性見解進行交叉核對，以確保一致性。品質保證方案包括專家反覆同儕審查和敏感度分析，以檢驗策略建議在不同情境下的穩健性。

適用情況下，會註明限制。此外，由於監管和政策的快速變化，企業發展可能會在研究期結束後發生變化。儘管如此，該調查方法透明且可複製，相關人員可以根據自身組織需求進行調整，或要求針對特定地區、產品類別或供應鏈環節進行後續分析。

結論綜合表明，需要將技術進步與供應鏈韌性和政策協調性相結合，以確保有效應對通用感染疾病。

我們的累積分析表明，僅靠科學進步不足以應對通用感染疾病生技藥品了前所未有的技術工具，但這些工具的價值取決於供應鏈的可靠性、監管體系的靈活性以及各地區臨床準備的深度。因此，策略投資必須在突破性創新與實際應用能力之間取得平衡，以確保產品在最需要的時候能夠惠及臨床醫生和患者。

同樣重要的是，要協調公共和私營部門相關人員的獎勵，以支持管理、公平獲取和永續的生產能力。當這些要素協調一致時，衛生系統將能更好地應對通用感染疾病帶來的臨床和經濟影響。該報告的洞見提出了明確的行動方案：加強基於平台的生產，將指南納入治療決策，實現供應鏈多元化，並深化區域夥伴關係，以便根據當地情況制定應對措施。

綜上所述，積極採取這些整合策略的組織將能夠增強自身抵禦通用感染疾病威脅的能力，加快患者獲得有效治療方法的速度，並更好地實現公共衛生和商業目標。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 透過整合 CRISPR 為基礎的診斷和治療平台，快速控制通用感染疾病
  • 部署mRNA疫苗技術以應對地方性流行區域的多種通用感染疾病
  • 針對宿主細胞路徑、預防通用感染疾病傳播的頻譜抗病毒小分子藥物的進展
  • 人工智慧驅動的流行病學模型在預測通用感染疾病爆發熱點地區和治療需求方面的應用日益廣泛
  • 增加對「同一健康」舉措的投入，將人類、動物和環境數據整合起來，以最佳化通用感染疾病的治療。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8.通用感染疾病治療市場（依疫苗分類）

  • 預防性疫苗
    • 衰減
    • 組合型
    • mRNA
    • 重組
  • 治療性疫苗
    • 衰減
    • 組合型
    • mRNA
    • 重組

9. 依治療藥物分類的通用感染疾病治療市場

  • 抗生素
    • BETA-內醯胺類
    • 大環內酯類
    • 四環黴素
  • 抗真菌藥物
    • Azole
    • Polyenes
  • 抗寄生蟲藥物
    • 驅蟲藥
    • 抗原生動物
  • 抗病毒藥物
    • 單株抗體
    • 核苷
    • 蛋白酶抑制劑

10. 依診斷方法分類的通用感染疾病治療市場

  • 影像
    • X光檢查
    • 超音波
  • 分子診斷
    • 次世代定序
    • PCR
  • 照護現場
    • 橫向流動化驗
  • 血清學
    • ELISA
    • 快速檢測

第11章通用感染疾病治療市場（依支持性照護分類）

  • 點滴
  • 營養
  • 疼痛管理
    • 止痛藥
    • NSAIDs

第12章：按地區分類的通用感染疾病治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章通用感染疾病治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國通用感染疾病治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • GlaxoSmithKline plc
    • Sanofi SA
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Johnson & Johnson
    • Moderna, Inc.
    • CSL Limited
    • Novavax, Inc.
    • Valneva SE
    • Bavarian Nordic A/S
Product Code: MRR-0315DDADCE31

The Zoonotic Disease Treatment Market is projected to grow by USD 62.19 billion at a CAGR of 5.61% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 40.16 billion
Estimated Year [2025] USD 42.44 billion
Forecast Year [2032] USD 62.19 billion
CAGR (%) 5.61%

Comprehensive contextual overview of zoonotic disease threats and the integrated clinical and public health responses needed to protect populations

Zoonotic diseases remain a persistent and evolving threat to human and animal health, demanding a coordinated response across public health, clinical medicine, and commercial stakeholders. Rising pathogen spillover events, accelerated by global travel, land use change, and shifting animal-human interfaces, have amplified the urgency of robust prevention, diagnostic, and treatment capabilities. Consequently, institutions responsible for preparedness must reconcile short-term clinical imperatives with longer-term investments in platform technologies and health-system resilience.

This landscape requires decision-makers to adopt integrated frameworks that align vaccine development, therapeutic innovation, diagnostics deployment, and supportive care delivery. From the outset, a systems perspective clarifies interdependencies: effective therapeutics depend on rapid and accurate diagnostics; vaccine strategies are informed by genomic surveillance; and supportive care capacity underpins clinical outcomes in severe zoonotic infections. In addition, public-private collaboration is critical to transforming scientific advances into scalable interventions that reach diverse healthcare settings.

Therefore, stakeholders should prioritize interoperable surveillance systems, adaptable manufacturing capacity, and evidence-driven clinical pathways. These priorities reflect both the technical realities of pathogen biology and the logistical constraints that determine real-world impact. As this executive summary outlines, the convergence of scientific innovation and pragmatic operational design will define how health systems mitigate the next wave of zoonotic challenges.

Recent years have witnessed transformative shifts in the zoonotic disease treatment landscape, driven by platform innovations, regulatory evolution, and a maturation of the One Health paradigm. Suite-based vaccine platforms, particularly those enabling rapid antigen design and scalable manufacturing, have accelerated the timeline from sequence to candidate, while parallel advances in monoclonal antibodies and small-molecule antivirals have diversified therapeutic arsenals. At the same time, regulatory pathways are adapting to accommodate platform-based approvals and expedited review mechanisms, which collectively lower barriers to rapid countermeasure deployment.

Technological advances in diagnostics have also reconfigured clinical workflows; molecular methods such as PCR and next-generation sequencing complement point-of-care modalities to enable earlier detection and pathogen characterization. This diagnostic continuum supports more targeted therapeutic decisions and reduces unnecessary antimicrobial exposure. Meanwhile, digital health tools and data integration platforms are enabling near real-time surveillance and patient management, linking community-level signals with hospital response capacity.

Concurrently, there has been a strategic shift toward integrated preparedness financing and multisectoral partnerships. Public and private funders are increasingly underwriting ecosystem-level investments-such as surge manufacturing capabilities and supply chain diversification-to mitigate the risk of shortages during outbreaks. As a result, organizations that combine scientific agility with operational rigor are best positioned to convert these shifts into improved clinical outcomes and sustained resilience.

Strategic assessment of how evolving tariff policies alter supply chains, procurement practices, and sustained access to diagnostics, therapeutics, and vaccines

Policy adjustments to trade and tariffs can materially influence access to critical medical countermeasures and the supply chains that support them. Tariff changes affecting raw materials, active pharmaceutical ingredients, diagnostics reagents, and finished biologics create ripple effects that alter procurement strategies, inventory practices, and sourcing decisions across the healthcare ecosystem. When tariffs increase costs or introduce uncertainty, organizations often respond by lengthening supply chains, accelerating localization of production, or prioritizing pre-positioning of strategic buffer stocks.

In addition to procurement impacts, tariffs reshape commercial calculus for manufacturers and contract service providers. They can influence decisions on where to site manufacturing capacity, whether to invest in redundant facilities, and how to price products for different markets. Importantly, these policy shifts interact with existing regulatory and logistics constraints, creating complex trade-offs between cost, speed, and supply security. For health systems managing outbreaks, the immediate concern is continuity of access to diagnostics, therapeutics, and vaccines; longer-term implications relate to the resilience of domestic manufacturing and the agility of cross-border distribution networks.

Consequently, stakeholders should treat tariff environments as a strategic risk that warrants scenario planning and active engagement with trade authorities. Organizations can mitigate exposure by diversifying supplier bases across jurisdictions, investing in modular and flexible production technologies, and developing contracting strategies that account for import duties and potential regulatory frictions. Ultimately, aligning procurement and manufacturing decisions with robust policy scans will better position clinical and commercial leaders to sustain treatment pathways during periods of geopolitical or trade policy disruption.

In-depth segmentation-driven analysis revealing how distinctions across vaccines, therapeutics, diagnostics, and supportive care dictate clinical priorities and commercial strategies

Effective segmentation analysis reveals where investment and operational focus are most likely to influence clinical outcomes and commercial viability. Within the vaccines domain, distinctions between preventive and therapeutic vaccines shape development priorities and manufacturing footprints. Preventive vaccine pathways include attenuated, conjugate, mRNA, and recombinant approaches, each requiring distinct cold chain, adjuvant, and regulatory considerations. Therapeutic vaccines similarly encompass attenuated, conjugate, mRNA, and recombinant classes but are developed with different efficacy endpoints and clinical trial designs that influence market entry timelines and physician adoption curves.

Therapeutics segmentation likewise clarifies clinical and supply-side dynamics. Antibiotics, antifungals, antiparasitics, and antivirals represent core treatment classes, with antibiotics subdivided into beta-lactams, macrolides, and tetracyclines, each with legacy manufacturing bases and stewardship imperatives. Antifungal assets concentrate in azoles and polyenes, reflecting distinct pharmacokinetics and toxicity profiles, while antiparasitic strategies split into anthelmintics and antiprotozoals, which require targeted delivery modalities. Antiviral portfolios that include monoclonal antibodies, nucleoside analogues, and protease inhibitors demand advanced biologics or synthetic chemistry capabilities and close coordination with diagnostic platforms for appropriate use.

Diagnostics segmentation highlights the need for an ecosystem approach that spans imaging, molecular diagnostics, point-of-care tools, and serology. Imaging modalities such as radiography and ultrasound support clinical triage and complication assessment, whereas molecular diagnostics leverage next-generation sequencing and PCR for pathogen identification and genomic surveillance. Point-of-care lateral flow assays enable rapid screening in decentralized settings, and serology assays, including ELISA and rapid test formats, provide epidemiologic context and insights into immune responses. Supportive care segmentation, encompassing fluids, nutrition, and pain management, frames essential clinical interventions, with pain management further divided into analgesics and NSAIDs; these components underpin patient recovery trajectories and health system capacity planning.

Taken together, these segmentation lenses inform where clinical need intersects with manufacturing feasibility and commercial potential, guiding prioritized investments across platforms and product classes.

Regional strategic perspectives that reconcile manufacturing capacity, regulatory diversity, and logistical realities to enable equitable access to treatments and diagnostics

Regional dynamics shape both the operational realities of delivering care and the strategic approaches to research, development, and distribution. The Americas demonstrate a concentrated ecosystem of advanced biomanufacturing, extensive clinical trial capacity, and complex payer landscapes; these factors favor high-throughput platform technologies and sophisticated diagnostic integration but also create cost and access considerations for underserved populations. In contrast, Europe, Middle East & Africa encompasses a diverse array of regulatory environments and health infrastructure maturity, where centralized regulatory harmonization efforts coexist with localized procurement practices and varying capability in cold chain logistics.

Asia-Pacific is characterized by a blend of rapid manufacturing scale-up, strong generic pharmaceutical capabilities, and an expanding base of research-intensive entities. This region's heterogeneity includes high-capacity urban centers alongside remote areas that depend on point-of-care diagnostics and decentralized supply models. Across all regions, climate-related changes and shifting land use patterns influence zoonotic risk profiles, requiring region-specific surveillance and community engagement strategies.

Therefore, strategy must be regionally adaptable: manufacturing and supply plans should reflect local regulatory requirements and logistical constraints, while clinical adoption efforts must align with payer dynamics and health system workflows. Partnerships that bridge regional strengths-such as technology transfer agreements, regulatory cooperation, and shared surveillance platforms-can accelerate equitable access and reduce response times during outbreak scenarios.

Competitive dynamics and partnership-driven strategies that define market positioning and operational advantages across vaccine, therapeutic, and diagnostics providers

Competitive dynamics in the zoonotic disease treatment space are shaped by a mix of established pharmaceutical firms, specialized biotechnology companies, diagnostics manufacturers, and agile contract development and manufacturing organizations. Industry leaders are differentiating through investments in platform technologies that reduce development lead times and enable rapid scale-up. In parallel, specialized firms with targeted expertise in molecular diagnostics or biologics are carving out crucial roles through focused innovation and niche clinical partnerships.

Strategic alliances and partnerships are increasingly central to pipeline progression and market access. Co-development agreements between platform owners and regional manufacturers help bridge capacity gaps, while collaborations with academic and public health institutions provide deep expertise in pathogen biology and clinical trial networks. Intellectual property strategies are being balanced against the imperative for broad access during public health emergencies, prompting creative licensing and technology transfer arrangements.

Operational excellence remains a competitive advantage: companies that demonstrate reliable supply continuity, transparent quality systems, and clear regulatory pathways secure preferential procurement and stronger clinician confidence. Additionally, entrants that align product design with real-world clinical settings-such as thermostable formulations, simplified administration, and integrated diagnostics-achieve faster uptake. In this environment, companies that integrate scientific leadership with scaled manufacturing and pragmatic commercialization strategies will maintain the most durable competitive positions.

Practical and prioritized actions for industry leaders to strengthen manufacturing agility, align diagnostics with therapeutics, and uphold equitable access in outbreak scenarios

Industry leaders should prioritize a set of actionable steps that bridge innovation with operational resilience and access. First, invest in modular and platform-based manufacturing approaches that permit rapid retooling across vaccine and biologic candidates, thereby enabling nimble responses to emergent pathogens. This capability should be paired with diversified supplier networks for critical raw materials to reduce single-point-of-failure risks.

Second, integrate diagnostics into therapeutic strategies by developing co-dependent solutions that link rapid molecular or point-of-care testing to appropriate treatment pathways. Doing so reduces unnecessary antimicrobial use and improves clinical outcomes through targeted therapy. Third, strengthen stewardship frameworks for antimicrobials and antivirals by collaborating with clinicians and public health authorities to align prescribing practices with surveillance data and resistance trends. Fourth, engage proactively with regulatory authorities to leverage adaptive approvals for platform technologies and to streamline trial designs that yield robust evidence while accelerating access.

Fifth, embed digital surveillance and data-sharing agreements that facilitate near real-time situational awareness across public and private stakeholders. Finally, design equitable access strategies that include flexible pricing, technology transfer, and capacity building in lower-resourced settings to ensure interventions reach the patients who need them most. Implemented in concert, these steps improve both readiness and the sustainability of commercial models in a high-stakes therapeutic area.

Transparent mixed-methods research approach combining expert interviews, systematic review, and triangulation to produce credible and actionable insights for decision-makers

This research synthesizes primary and secondary evidence using a mixed-methods approach designed to produce actionable and verifiable insights. Primary research included structured interviews with clinical leaders, regulatory experts, supply chain managers, and senior executives across vaccine, therapeutic, and diagnostics organizations, providing context on operational constraints and strategic priorities. Secondary research consisted of a systematic review of peer-reviewed literature, regulatory guidance documents, technical white papers, and public health reports to ground findings in established science and policy trends.

Data triangulation methods were applied to reconcile divergent perspectives and to validate thematic conclusions. Quantitative inputs such as manufacturing lead times, clinical trial design parameters, and regulatory submission processes were cross-checked against qualitative insights gleaned from expert consultations to ensure consistency. Quality assurance protocols included iterative peer review among subject-matter experts and sensitivity analyses to test the robustness of strategic recommendations under alternative scenarios.

Where applicable, limitations are acknowledged: confidential commercial data were not accessible in all instances, and rapidly evolving regulatory or policy shifts may alter operational dynamics beyond the study window. Nevertheless, the methodology emphasizes transparency and replicability, enabling stakeholders to adapt the approach to their organizational needs and to request targeted follow-up analyses for specific geographies, product classes, or supply chain components.

Concluding synthesis emphasizing the necessity of integrating technological advances with supply chain resilience and policy alignment to ensure effective responses to zoonotic threats

The cumulative analysis underscores that scientific progress alone is insufficient without coordinated operational and policy responses. Advances in vaccine platforms, biologics, and diagnostics provide unprecedented technical tools to prevent and treat zoonotic diseases, but the value of these tools depends on the reliability of supply chains, the agility of regulatory systems, and the depth of clinical readiness across regions. Therefore, strategic investments must balance breakthrough innovation with pragmatic execution capabilities that ensure products reach clinicians and patients when they are most needed.

Equally important is the alignment of incentives across public and private actors to support stewardship, equitable access, and sustained manufacturing capacity. When these elements are harmonized, the health system is better prepared to limit the clinical and economic impacts of zoonotic events. The report's insights point to clear pathways for action: strengthen platform-based manufacturing, integrate diagnostics into treatment decision-making, diversify supply chains, and deepen regional partnerships to tailor responses to local contexts.

In sum, organizations that proactively adopt these integrated strategies will improve resilience, accelerate patient access to effective interventions, and better fulfill both public health and commercial objectives amid the continuing challenge of zoonotic disease threats.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of CRISPR-based diagnostic and therapeutic platforms for rapid zoonotic disease control
  • 5.2. Deployment of mRNA vaccine technology to address multiple zoonotic pathogens in endemic regions
  • 5.3. Advances in broad-spectrum antiviral small molecules targeting host cell pathways to prevent zoonotic spillover
  • 5.4. Growing adoption of AI-driven epidemiological modeling to forecast zoonotic outbreak hotspots and treatment needs
  • 5.5. Rising investment in One Health initiatives integrating human, animal, and environmental data for zoonotic disease treatment optimization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Zoonotic Disease Treatment Market, by Vaccines

  • 8.1. Preventive Vaccines
    • 8.1.1. Attenuated
    • 8.1.2. Conjugate
    • 8.1.3. mRNA
    • 8.1.4. Recombinant
  • 8.2. Therapeutic Vaccines
    • 8.2.1. Attenuated
    • 8.2.2. Conjugate
    • 8.2.3. mRNA
    • 8.2.4. Recombinant

9. Zoonotic Disease Treatment Market, by Therapeutics

  • 9.1. Antibiotics
    • 9.1.1. Beta-Lactams
    • 9.1.2. Macrolides
    • 9.1.3. Tetracyclines
  • 9.2. Antifungals
    • 9.2.1. Azoles
    • 9.2.2. Polyenes
  • 9.3. Antiparasitics
    • 9.3.1. Anthelmintics
    • 9.3.2. Antiprotozoals
  • 9.4. Antivirals
    • 9.4.1. mAb
    • 9.4.2. Nucleoside
    • 9.4.3. Protease Inhibitors

10. Zoonotic Disease Treatment Market, by Diagnostics

  • 10.1. Imaging
    • 10.1.1. Radiography
    • 10.1.2. Ultrasound
  • 10.2. Molecular Diagnostics
    • 10.2.1. Next Generation Sequencing
    • 10.2.2. PCR
  • 10.3. Point Of Care
    • 10.3.1. Lateral Flow Assays
  • 10.4. Serology
    • 10.4.1. ELISA
    • 10.4.2. Rapid Test

11. Zoonotic Disease Treatment Market, by Supportive Care

  • 11.1. Fluids
  • 11.2. Nutrition
  • 11.3. Pain Management
    • 11.3.1. Analgesics
    • 11.3.2. NSAIDs

12. Zoonotic Disease Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Zoonotic Disease Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Zoonotic Disease Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. GlaxoSmithKline plc
    • 15.3.2. Sanofi S.A.
    • 15.3.3. Pfizer Inc.
    • 15.3.4. Merck & Co., Inc.
    • 15.3.5. Johnson & Johnson
    • 15.3.6. Moderna, Inc.
    • 15.3.7. CSL Limited
    • 15.3.8. Novavax, Inc.
    • 15.3.9. Valneva SE
    • 15.3.10. Bavarian Nordic A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ZOONOTIC DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ZOONOTIC DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ZOONOTIC DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY BETA-LACTAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY BETA-LACTAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY BETA-LACTAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY BETA-LACTAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NUCLEOSIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NUCLEOSIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NUCLEOSIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NUCLEOSIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NUCLEOSIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NUCLEOSIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RADIOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RADIOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RADIOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RADIOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RADIOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RADIOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POINT OF CARE, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POINT OF CARE, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RAPID TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RAPID TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RAPID TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RAPID TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY RAPID TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY FLUIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY FLUIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY FLUIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY FLUIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY FLUIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY FLUIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NUTRITION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NUTRITION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NUTRITION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NUTRITION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NUTRITION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NUTRITION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANALGESICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANALGESICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POINT OF CARE, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY POINT OF CARE, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-